Carl Borrebaeck
Carl Borrebaeck is a professor at the Department of Immunotechnology and chairman of the CREATE Health translational cancer research center at Lund University. He is an entrepreneur and founded SenzaGen AB and several other life science companies, including Immunovia AB, Alligator Bioscience AB and BioInvent International AB. He is also a founding mentor for the Nordic Mentor Network for Entrepreneurship (NOME), a member of the Royal Swedish Academy of Engineering Sciences (IVA) and former vice-chancellor at Lund University. Carl has won a number of awards for his entrepreneurship and groundbreaking research, including AkzoNobel’s Science Prize in 2009, the Royal Swedish Academy of Engineering Sciences (IVA) Gold Medal in 2012, and the Biotech Builder Award in 2017.
Education: Professor of Immunotechnology, DSc major in molecular immunology, MSc in Chemical Engineering, MSc in Life Science.
Other appointments: Board chairman of PainDrainer AB and CB Ocean Capital AB.
Shareholding: 1,694,000 shares.
Independance: Independent in relation to the company, the company’s senior executives and major shareholders of the company.
Ian Kimber
Ian Kimber is Emeritus Professor of Toxicology at the University of Manchester. He has extensive experience in academia, as well as in the pharmaceutical, biopharmaceutical, and agrochemical industries, and as an independent consultant. Professor Kimber has won several prestigious awards for his scientific and research contributions, including the Society of Toxicology Distinguished Toxicology Scholar Award (2015). He received the OBE for Services to Science in the Queen’s Birthday Honours List (2011). He also serves on numerous expert committees and scientific advisory groups both in the UK and internationally.
Education: Professor of Toxicology. PhD, MSc, BSc.
Other appointments: –
Shareholding: 1,500 shares.
Independence: Independent in relation to the company, the company’s senior executives and major shareholders of the company.
Anki Malmborg Hager
Anki Malmborg Hager has extensive expe¬rience from starting life science companies originating from Lund university research. Anki served as CEO of SenzaGen from 2014 to 2019. Her past experience includes CEO of PainDrainer AB, Cantargia AB, XImmune AB and Diaprost AB, and before that, Investment Director at LU Bioscience AB and VP Business Development at Alligator Bioscience AB.
Education: PhD in Immunotechnology, MSc in Chemical Engineering, Pharma MBA.
Other appointments: CEO of Lead Biologics International AB. Board director at NanoEcho AB, Pharma Holdings and Hager Consulting AB.
Shareholding: 385,000 shares.
Independence: Independent in relation to the company, the company’s senior executives and major shareholders of the company.
Paul Yianni
Paul Yianni runs his own consulting business with a focus on business development, strategy and business coaching. Paul has over 30 years of management experience from the chemicals industry, and he has broad international experience from various technical and commercial functions, including at Dow Corning and Shell Chemicals. His previous positions include CEO of Spolchemie in Czechia and head of M&A at DIC Europe in Germany.
Education: PhD in Chemistry.
Other appointments: –
Shareholding: 100,000 shares.
Independence: Independent in relation to the company, the company’s senior executives and major shareholders of the company.
Paula Zeilon
Paula Zeilon has 30 years of management experience from the life science industry and runs her own consulting business in the fields of business development and management focusing on the commercialization of new products on international markets. Her past experience includes CEO of Life Science Foresight Institute, CEO of Alligator Biosciences AB, Director Marketing at Dako A/S, Director Marketing at Biotage AB, and management positions with Pharmacia Biotech (now Cytiva).
Education: MSc Chemical engineering, Business Administration.
Other appointments: –
Shareholding: 7,800 shares.
Independence: Independent in relation to the company, the company’s senior executives and major shareholders of the company.
Updated 2025-05-27
